Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies

An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty acid synthase (FASN) is overexpressed in many cancers and is pivotal for the increased production of fatty acids. There is increasing evidences...

Full description

Saved in:
Bibliographic Details
Published in:Oncogenesis (New York, NY) Vol. 12; no. 1; pp. 16 - 10
Main Authors: Vanauberg, Dimitri, Schulz, Céline, Lefebvre, Tony
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 18.03.2023
Nature Publishing Group
Subjects:
631/154/53
631/67/395
Angiogenesis
Apoptosis
Cancer
Cancer therapies
Cell activation
Cell Biology
Cell death
Cell growth
Cell proliferation
Chemotherapy
Enzymes
ErbB-2 protein
Fatty acids
Fatty-acid synthase
Human Genetics
Immunoregulation
Inflammation
Internal Medicine
Lipid rafts
Lipogenesis
Localization
Lymphocytes T
Macrophages
Medicine
Medicine & Public Health
Metastases
Oncology
Protein biosynthesis
Review
Review Article
Tumor microenvironment
ISSN:2157-9024, 2157-9024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty acid synthase (FASN) is overexpressed in many cancers and is pivotal for the increased production of fatty acids. There is increasing evidences of the involvement of FASN in several hallmarks of cancer linked to its ability to promote cell proliferation via membranes biosynthesis. In this review we discuss about the implication of FASN in the resistance to cell death and in the deregulation of cellular energetics by increasing nucleic acids, protein and lipid synthesis. FASN also promotes cell proliferation, cell invasion, metastasis and angiogenesis by enabling the building of lipid rafts and consequently to the localization of oncogenic receptors such as HER2 and c-Met in membrane microdomains. Finally, FASN is involved in immune escape by repressing the activation of pro-inflammatory cells and promoting the recruitment of M2 macrophages and T regulatory cells in the tumor microenvironment. Here, we provide an overview of the involvement of the pro-oncogenic enzyme in the hallmarks of cancer making FASN a promising target in anti-cancer therapy to circumvent resistance to chemotherapies.
AbstractList An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty acid synthase (FASN) is overexpressed in many cancers and is pivotal for the increased production of fatty acids. There is increasing evidences of the involvement of FASN in several hallmarks of cancer linked to its ability to promote cell proliferation via membranes biosynthesis. In this review we discuss about the implication of FASN in the resistance to cell death and in the deregulation of cellular energetics by increasing nucleic acids, protein and lipid synthesis. FASN also promotes cell proliferation, cell invasion, metastasis and angiogenesis by enabling the building of lipid rafts and consequently to the localization of oncogenic receptors such as HER2 and c-Met in membrane microdomains. Finally, FASN is involved in immune escape by repressing the activation of pro-inflammatory cells and promoting the recruitment of M2 macrophages and T regulatory cells in the tumor microenvironment. Here, we provide an overview of the involvement of the pro-oncogenic enzyme in the hallmarks of cancer making FASN a promising target in anti-cancer therapy to circumvent resistance to chemotherapies.
An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty acid synthase (FASN) is overexpressed in many cancers and is pivotal for the increased production of fatty acids. There is increasing evidences of the involvement of FASN in several hallmarks of cancer linked to its ability to promote cell proliferation via membranes biosynthesis. In this review we discuss about the implication of FASN in the resistance to cell death and in the deregulation of cellular energetics by increasing nucleic acids, protein and lipid synthesis. FASN also promotes cell proliferation, cell invasion, metastasis and angiogenesis by enabling the building of lipid rafts and consequently to the localization of oncogenic receptors such as HER2 and c-Met in membrane microdomains. Finally, FASN is involved in immune escape by repressing the activation of pro-inflammatory cells and promoting the recruitment of M2 macrophages and T regulatory cells in the tumor microenvironment. Here, we provide an overview of the involvement of the pro-oncogenic enzyme in the hallmarks of cancer making FASN a promising target in anti-cancer therapy to circumvent resistance to chemotherapies.An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty acid synthase (FASN) is overexpressed in many cancers and is pivotal for the increased production of fatty acids. There is increasing evidences of the involvement of FASN in several hallmarks of cancer linked to its ability to promote cell proliferation via membranes biosynthesis. In this review we discuss about the implication of FASN in the resistance to cell death and in the deregulation of cellular energetics by increasing nucleic acids, protein and lipid synthesis. FASN also promotes cell proliferation, cell invasion, metastasis and angiogenesis by enabling the building of lipid rafts and consequently to the localization of oncogenic receptors such as HER2 and c-Met in membrane microdomains. Finally, FASN is involved in immune escape by repressing the activation of pro-inflammatory cells and promoting the recruitment of M2 macrophages and T regulatory cells in the tumor microenvironment. Here, we provide an overview of the involvement of the pro-oncogenic enzyme in the hallmarks of cancer making FASN a promising target in anti-cancer therapy to circumvent resistance to chemotherapies.
Abstract An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty acid synthase (FASN) is overexpressed in many cancers and is pivotal for the increased production of fatty acids. There is increasing evidences of the involvement of FASN in several hallmarks of cancer linked to its ability to promote cell proliferation via membranes biosynthesis. In this review we discuss about the implication of FASN in the resistance to cell death and in the deregulation of cellular energetics by increasing nucleic acids, protein and lipid synthesis. FASN also promotes cell proliferation, cell invasion, metastasis and angiogenesis by enabling the building of lipid rafts and consequently to the localization of oncogenic receptors such as HER2 and c-Met in membrane microdomains. Finally, FASN is involved in immune escape by repressing the activation of pro-inflammatory cells and promoting the recruitment of M2 macrophages and T regulatory cells in the tumor microenvironment. Here, we provide an overview of the involvement of the pro-oncogenic enzyme in the hallmarks of cancer making FASN a promising target in anti-cancer therapy to circumvent resistance to chemotherapies.
ArticleNumber 16
Author Vanauberg, Dimitri
Lefebvre, Tony
Schulz, Céline
Author_xml – sequence: 1
  givenname: Dimitri
  orcidid: 0000-0002-6205-945X
  surname: Vanauberg
  fullname: Vanauberg, Dimitri
  organization: Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle
– sequence: 2
  givenname: Céline
  surname: Schulz
  fullname: Schulz, Céline
  organization: Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle
– sequence: 3
  givenname: Tony
  surname: Lefebvre
  fullname: Lefebvre, Tony
  email: tony.lefebvre@univ-lille.fr
  organization: Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36934087$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAURiNURMvQF2CBIrFhE3AcJ7HZIFTxM1IlNrC2bpzrjIfEHmzPSMOWF8eZtNB20WwSOec7-nR9n2dn1lnMspcleVuSir8LrKy4KAitCkJYQwr-JLugZd0WglB2duf7PLsMYUvSUzdlU9fPsvOqERUjvL3I_qztwY0HnNDG3Ok8bjDfeVc4q9yA1qgc7e_jhLmGGI85KNPn4WjjBgLmxp74DYzjBP5nmAUKrEL_PodZM5lg7JBH8APGGQcbTbEgc9TDzmB4kT3VMAa8vHmvsh-fP32_-lpcf_uyvvp4XaialbHoNEemG1BUNB3vNO2gZ5r3fdcyBgpJxwW0ildCC4KKIlGUqJpWiKoWrKlW2Xrx9g62cudNKn2UDow8HTg_SPDRqBGlUtB1QqXpkZY1mgCt27LuGBDUogSSXB8W127fTdirND4P4z3p_T_WbOTgDrIkSdqma1tlb24M3v3aY4gyTUvhOIJFtw-Stpy3gtc1S-jrB-jW7b1Ns5qpVghG6Sx8dbfSvy63l50AvgDKuxA8aqlMhGjc3NCMqZqcV0suqyVTR3laLclTlD6I3tofDVVLKCTYDuj_134k9Re25-Ne
CitedBy_id crossref_primary_10_1016_j_bbalip_2024_159531
crossref_primary_10_2147_JHC_S447578
crossref_primary_10_3389_fphar_2025_1674752
crossref_primary_10_1111_apha_14164
crossref_primary_10_3390_ph17010096
crossref_primary_10_1002_cam4_70975
crossref_primary_10_1038_s41586_025_08782_w
crossref_primary_10_1016_j_clinsp_2025_100697
crossref_primary_10_3390_cancers16030504
crossref_primary_10_3390_ijms26010092
crossref_primary_10_1002_1878_0261_13582
crossref_primary_10_1016_j_ijpharm_2025_125574
crossref_primary_10_1080_09553002_2024_2446585
crossref_primary_10_3892_mmr_2025_13448
crossref_primary_10_3390_ijms25115918
crossref_primary_10_3390_ijms26157508
crossref_primary_10_1080_14728222_2025_2532394
crossref_primary_10_1093_bioinformatics_btaf142
crossref_primary_10_3390_life15010126
crossref_primary_10_1016_j_cbi_2024_110991
crossref_primary_10_1016_j_chemosphere_2024_142332
crossref_primary_10_1038_s41419_024_06463_6
crossref_primary_10_1053_j_gastro_2024_05_005
crossref_primary_10_3390_metabo15070428
crossref_primary_10_1016_j_bbalip_2025_159634
crossref_primary_10_3390_molecules30142891
crossref_primary_10_1111_febs_70081
crossref_primary_10_3390_polym16233260
crossref_primary_10_1016_j_gendis_2025_101772
crossref_primary_10_1007_s12032_024_02435_0
crossref_primary_10_1016_j_yexmp_2025_104980
crossref_primary_10_3390_ijms25105482
crossref_primary_10_1016_j_jbc_2025_110497
crossref_primary_10_1186_s12944_024_02088_y
crossref_primary_10_3390_ijms241411786
crossref_primary_10_3390_biomedicines12030541
crossref_primary_10_3390_cancers17010054
crossref_primary_10_1016_j_abb_2023_109825
crossref_primary_10_1016_j_cellsig_2025_111823
crossref_primary_10_1038_s41467_025_58158_x
crossref_primary_10_1002_cbf_3934
crossref_primary_10_1186_s12943_024_02119_3
crossref_primary_10_1021_jacs_4c05938
crossref_primary_10_1073_pnas_2412914121
crossref_primary_10_1097_CJI_0000000000000534
crossref_primary_10_1007_s12013_024_01339_0
crossref_primary_10_1016_j_prp_2024_155465
crossref_primary_10_1038_s41420_024_02184_z
crossref_primary_10_3390_ijms25126509
crossref_primary_10_1016_j_semcancer_2025_06_005
crossref_primary_10_3390_cancers17142341
crossref_primary_10_1016_j_critrevonc_2025_104910
crossref_primary_10_1186_s12967_025_06248_1
Cites_doi 10.1093/ajcp/97.5.686
10.1158/0008-5472.CAN-15-0202
10.1016/j.cell.2011.02.013
10.1016/j.celrep.2021.110174
10.1038/bjc.2012.355
10.1126/science.1161269
10.1016/j.ccell.2017.11.011
10.1186/bcr2777
10.1034/j.1600-0560.2003.300104.x
10.4161/cbt.5.8.2883
10.1023/B:BREA.0000018409.59448.60
10.1080/1120009X.2019.1694761
10.3390/cancers12051283
10.1007/s00018-021-03857-z
10.1016/j.mehy.2004.09.027
10.1371/journal.pone.0097697
10.1371/journal.pone.0147717
10.2147/OTT.S199369
10.1021/jf2021489
10.1152/ajplung.1999.277.2.L381
10.1016/s0163-7827(02)00067-x
10.4161/cc.7.14.6475
10.3892/or.2014.3484
10.1073/pnas.0931394100
10.1152/ajpendo.00514.2013
10.1073/pnas.1205995109
10.1016/j.mtbio.2021.100155
10.1002/mc.20649
10.1096/fj.05-5404com
10.1046/j.1365-2559.2002.01289.x
10.7150/ijbs.7357
10.1051/medsci/2022062
10.1007/s00432-016-2249-6
10.3892/ijo.2014.2441
10.1158/1538-7445.AM2017-CT153
10.1053/j.gastro.2010.12.006
10.1038/s41588-017-0027-2
10.3892/ol.2022.13239
10.1093/gerona/glr124
10.1080/15384101.2017.1282586
10.1136/jitc-2021-003093
10.1158/1078-0432.CCR-15-2973
10.1038/s41586-021-03235-6
10.1073/pnas.91.14.6379
10.1158/1055-9965.EPI-09-0144
10.1016/j.bbalip.2018.12.011
10.3390/cancers13051132
10.1002/ijc.20754
10.1093/jnci/djp030
10.4161/cbt.10.6.12727
10.1007/s12032-014-0391-z
10.3892/ol.2022.13225
10.1038/srep14752
10.1038/s43018-021-00183-y
10.15252/emmm.201708313
10.3389/fimmu.2018.02927
10.1007/s10549-021-06231-6
10.1038/d41573-021-00052-4
10.3389/fonc.2021.725137
10.1093/carcin/bgu042
10.1016/j.cmet.2018.07.019
10.1016/j.chembiol.2004.09.016
10.1007/s00280-019-04010-1
10.1172/JCI148550
10.3892/or.2016.4682
10.1111/j.1365-2184.2007.00498.x
10.3892/ijo.31.4.769
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88A
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41389-023-00460-8
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Science Database (ProQuest)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
Publicly Available Content Database

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2157-9024
EndPage 10
ExternalDocumentID oai_doaj_org_article_ccabb9c0240746f0a25715b4a0ef91a0
PMC10024702
36934087
10_1038_s41389_023_00460_8
Genre Journal Article
Review
GroupedDBID 0R~
3V.
53G
5VS
7X7
88A
88I
8FE
8FH
8FI
8FJ
AAJSJ
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBLON
EBS
FYUFA
GNUQQ
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
KQ8
LK8
M0L
M2P
M48
M7P
M~E
NAO
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
CITATION
NPM
7XB
8FK
K9.
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c541t-bf8e4f6ac296b8bf2bad4f8ddb744ace0b89a7c839f90ec2e0c20c523eec59463
IEDL.DBID DOA
ISICitedReferencesCount 64
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000952323000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2157-9024
IngestDate Tue Oct 14 18:15:59 EDT 2025
Tue Nov 04 02:07:05 EST 2025
Fri Sep 05 12:53:04 EDT 2025
Sat Nov 29 14:22:26 EST 2025
Mon Jul 21 05:31:59 EDT 2025
Tue Nov 18 22:16:34 EST 2025
Sat Nov 29 02:53:39 EST 2025
Fri Feb 21 02:40:45 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-bf8e4f6ac296b8bf2bad4f8ddb744ace0b89a7c839f90ec2e0c20c523eec59463
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-6205-945X
OpenAccessLink https://doaj.org/article/ccabb9c0240746f0a25715b4a0ef91a0
PMID 36934087
PQID 2787994222
PQPubID 2041913
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_ccabb9c0240746f0a25715b4a0ef91a0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10024702
proquest_miscellaneous_2788798554
proquest_journals_2787994222
pubmed_primary_36934087
crossref_citationtrail_10_1038_s41389_023_00460_8
crossref_primary_10_1038_s41389_023_00460_8
springer_journals_10_1038_s41389_023_00460_8
PublicationCentury 2000
PublicationDate 2023-03-18
PublicationDateYYYYMMDD 2023-03-18
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-18
  day: 18
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
– name: New York
PublicationTitle Oncogenesis (New York, NY)
PublicationTitleAbbrev Oncogenesis
PublicationTitleAlternate Oncogenesis
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Browne, Hindmarsh, Smith (CR53) 2006; 20
Mounier, Bouraoui, Rassart (CR26) 2014; 45
Giudetti, De Domenico, Ragusa, Lunetti, Gaballo, Franck (CR27) 2019; 1864
Chen, Zhang, Sampieri, Clohessy, Mendez, Gonzalez-Billalabeitia (CR52) 2018; 50
Hanahan, Weinberg (CR25) 2011; 144
Gruslova, McClellan, Balinda, Viswanadhapalli, Alers, Sareddy (CR64) 2021; 187
Seguin, Carvalho, Bastos, Agostini, Zecchin, Alvarez-Flores (CR55) 2012; 107
Vazquez-Martin, Ropero, Brunet, Colomer, Menendez (CR68) 2007; 18
Lemberg, Gori, Tsukamoto, Rais, Slusher (CR62) 2022; 132
Zhou, Jin, Mi, Zhang, Zhang, Xu (CR22) 2016; 142
Lu, Sun, Wang, Zhang, He, Xu (CR35) 2019; 1
Bruning, Morales-Rodriguez, Kalucka, Goveia, Taverna, Queiroz (CR54) 2018; 28
Menendez, Vellon, Colomer, Lupu (CR70) 2005; 115
Orita, Coulter, Tully, Abe, Montgomery, Alvarez (CR15) 2010; 10
Zaytseva, Elliott, Rychahou, Mustain, Kim, Valentino (CR56) 2014; 35
Suburu, Shi, Wu, Wang, Samuel, Thomas (CR7) 2014; 306
Zhu, Gu, Lin, Zhou, Lu, Liu (CR29) 2021; 37
Cioccoloni, Aquino, Notarnicola, Caruso, Bonmassar, Zonfrillo (CR61) 2020; 32
Smith, Witkowski, Joshi (CR2) 2003; 42
Kusakabe, Nashimoto, Honma, Suzuki (CR14) 2002; 40
Menendez, Papadimitropoulou, Vander Steen, Cuyàs, Oza-Gajera, Verdura (CR67) 2021; 13
de Almeida, Mariano, Bastos, Cavassani, Raphelson, Mariano (CR59) 2020; 85
Yasumoto, Miyazaki, Vaidyan, Kagawa, Ebrahimi, Yamamoto (CR40) 2016; 11
Li, Dong, Wei, Wang, Zhang, Li (CR45) 2014; 10
Cai, Wang, Zhang, Wu, Yu, Tian (CR18) 2015; 32
Hao, Li, Zhang, Gao, Qiao, Li (CR19) 2014; 32
Kuhajda, Jenner, Wood, Hennigar, Jacobs, Dick (CR10) 1994; 91
Calvisi, Wang, Ho, Ladu, Lee, Mattu (CR31) 2011; 140
Migita, Ruiz, Fornari, Fiorentino, Priolo, Zadra (CR13) 2009; 101
Raab, Lefebvre (CR4) 2022; 38
Ferraro, Ali, Luengo, Kodack, Deik, Abbott (CR51) 2021; 2
Guri, Colombi, Dazert, Hindupur, Roszik, Moes (CR32) 2017; 32
Hung, Kuo, Chou, Su, Ho, Way (CR46) 2011; 59
Kuhla, Blei, Jaster, Vollmar (CR9) 2011; 66
Raab, Very, Duchêne, Rybarczyk, Jonckheere, El Yazidi-Belkoura (CR20) 2022; 23
Fan, Liang, Jiang, Li, Xun, Sun (CR44) 2016; 35
Rabionet, Polonio-Alcalá, Relat, Yeste, Sims-Mourtada, Kloxin (CR37) 2021; 12
Maier, Leibundgut, Ban (CR5) 2008; 321
Che, Pilo, Cigliano, Latte, Simile, Ribback (CR24) 2017; 16
Rashid, Pizer, Moga, Milgraum, Zahurak, Pasternack (CR12) 1997; 150
CR11
Nath, Li, Roberts, Chan (CR50) 2015; 5
Walter, Hong, Nyhan, Canto, Fedarko, Klein (CR17) 2009; 18
Witkowski, Ghosal, Joshi, Witkowska, Asturias, Smith (CR3) 2004; 1
De Schrijver, Brusselmans, Heyns, Verhoeven, Swinnen (CR42) 2003; 63
Gao, Lin, Zhu, Chen, Hou, Ding (CR43) 2006; 5
Wagle, Bui, Ballard, Shuman, Gonzales, Gonzales (CR8) 1999; 277
Shurbaji, Kuhajda, Pasternack, Thurmond (CR1) 1992; 97
Chirala, Chang, Matzuk, Abu-Elheiga, Mao, Mahon (CR6) 2003; 100
Duhon, Bigelow, Coleman, Steffan, Yu, Langston (CR47) 2010; 49
Jin, Yuan, Boulbes, Baek, Wang, Gomez-Cabello (CR36) 2010; 12
Di Vizio, Adam, Kim, Kim, Sotgia, Williams (CR49) 2008; 7
Yan, Wei, Minjuan, Yan, Jingyue, Wenchao (CR38) 2014; 9
Geng, Cheng, Wu, Yoo, Cheng, Guo (CR28) 2016; 22
Menendez, Vellon, Lupu (CR48) 2005; 64
Menendez, Lupu, Colomer (CR69) 2004; 84
Visca, Sebastiani, Botti, Diodoro, Lasagni, Romagnoli (CR16) 2004; 24
Innocenzi, Alò, Balzani, Sebastiani, Silipo, La Torre (CR21) 2003; 30
Ravi, Beheshti, Abermil, Lansigan, Kinlaw, Matthan (CR33) 2021; 11
Ali, Levantini, Teo, Goggi, Clohessy, Wu (CR39) 2018; 10
Southam, Khanim, Hayden, Constantinou, Koczula, Michell (CR30) 2015; 75
Raab, Gadault, Very, Decourcelle, Baldini, Schulz (CR34) 2021; 78
Polonio-Alcalá, Palomeras, Torres-Oteros, Relat, Planas, Feliu (CR72) 2020; 12
Liu, Zhang, Song, Gao, Liu (CR41) 2022; 23
Mullard (CR65) 2021; 20
CR66
Sun, Zhang, Wang, Ma, Xu, Wang (CR57) 2021; 9
Falchook, Patel, Infante, Arkenau, Dean (CR63) 2017; 77
Menendez, Colomer, Lupu (CR71) 2004; 12
Lim, Wei, Nguyen, Shi, Su, Palacios (CR58) 2021; 591
Jiang, Fang, Wang, Li, Wang (CR60) 2018; 9
Bhatt, Jacobs, Freemerman, Makowski, Rathmell, Dittmer (CR23) 2012; 109
A Kuhla (460_CR9) 2011; 66
D Duhon (460_CR47) 2010; 49
M Chen (460_CR52) 2018; 50
S Raab (460_CR20) 2022; 23
D Ravi (460_CR33) 2021; 11
SA Lim (460_CR58) 2021; 591
Y Cai (460_CR18) 2015; 32
YY Zaytseva (460_CR56) 2014; 35
460_CR11
DF Calvisi (460_CR31) 2011; 140
T Maier (460_CR5) 2008; 321
AD Southam (460_CR30) 2015; 75
JA Menendez (460_CR48) 2005; 64
A Gruslova (460_CR64) 2021; 187
JA Menendez (460_CR69) 2004; 84
JA Menendez (460_CR71) 2004; 12
KM Lemberg (460_CR62) 2022; 132
S Raab (460_CR4) 2022; 38
A Witkowski (460_CR3) 2004; 1
L Jiang (460_CR60) 2018; 9
P Sun (460_CR57) 2021; 9
A Mullard (460_CR65) 2021; 20
JA Menendez (460_CR70) 2005; 115
CM Hung (460_CR46) 2011; 59
JA Menendez (460_CR67) 2021; 13
G Cioccoloni (460_CR61) 2020; 32
460_CR66
A Vazquez-Martin (460_CR68) 2007; 18
Q Jin (460_CR36) 2010; 12
G Falchook (460_CR63) 2017; 77
MS Shurbaji (460_CR1) 1992; 97
AM Giudetti (460_CR27) 2019; 1864
D Innocenzi (460_CR21) 2003; 30
T Lu (460_CR35) 2019; 1
F Seguin (460_CR55) 2012; 107
A Nath (460_CR50) 2015; 5
H Orita (460_CR15) 2010; 10
S Wagle (460_CR8) 1999; 277
T Kusakabe (460_CR14) 2002; 40
T Migita (460_CR13) 2009; 101
K Walter (460_CR17) 2009; 18
Y Guri (460_CR32) 2017; 32
F Geng (460_CR28) 2016; 22
J Suburu (460_CR7) 2014; 306
LY de Almeida (460_CR59) 2020; 85
L Che (460_CR24) 2017; 16
E Polonio-Alcalá (460_CR72) 2020; 12
J Li (460_CR45) 2014; 10
FP Kuhajda (460_CR10) 1994; 91
AP Bhatt (460_CR23) 2012; 109
CD Browne (460_CR53) 2006; 20
C Mounier (460_CR26) 2014; 45
A Rashid (460_CR12) 1997; 150
D Di Vizio (460_CR49) 2008; 7
SS Chirala (460_CR6) 2003; 100
Y Gao (460_CR43) 2006; 5
C Yan (460_CR38) 2014; 9
E De Schrijver (460_CR42) 2003; 63
Y Zhou (460_CR22) 2016; 142
Q Hao (460_CR19) 2014; 32
H Fan (460_CR44) 2016; 35
S Raab (460_CR34) 2021; 78
A Ali (460_CR39) 2018; 10
S Smith (460_CR2) 2003; 42
Y Zhu (460_CR29) 2021; 37
D Hanahan (460_CR25) 2011; 144
GB Ferraro (460_CR51) 2021; 2
P Visca (460_CR16) 2004; 24
Y Yasumoto (460_CR40) 2016; 11
U Bruning (460_CR54) 2018; 28
M Rabionet (460_CR37) 2021; 12
H Liu (460_CR41) 2022; 23
References_xml – volume: 97
  start-page: 686
  year: 1992
  end-page: 91
  ident: CR1
  article-title: Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator
  publication-title: Am J Clin Pathol
  doi: 10.1093/ajcp/97.5.686
– volume: 75
  start-page: 2530
  year: 2015
  end-page: 40
  ident: CR30
  article-title: Drug redeployment to kill leukemia and lymphoma cells by disrupting scd1-mediated synthesis of monounsaturated fatty acids
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-0202
– volume: 144
  start-page: 646
  year: 2011
  end-page: 74
  ident: CR25
  article-title: Hallmarks of cancer: the next generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 37
  start-page: 110174
  year: 2021
  ident: CR29
  article-title: USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.110174
– volume: 107
  start-page: 977
  year: 2012
  end-page: 87
  ident: CR55
  article-title: The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.355
– volume: 63
  start-page: 3799
  year: 2003
  end-page: 804
  ident: CR42
  article-title: RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells
  publication-title: Cancer Res
– volume: 321
  start-page: 1315
  year: 2008
  end-page: 22
  ident: CR5
  article-title: The crystal structure of a mammalian fatty acid synthase
  publication-title: Science
  doi: 10.1126/science.1161269
– volume: 32
  start-page: 807
  year: 2017
  end-page: 23.e12
  ident: CR32
  article-title: mTORC2 Promotes Tumorigenesis via Lipid Synthesis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.11.011
– volume: 12
  year: 2010
  ident: CR36
  article-title: Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2777
– volume: 30
  start-page: 23
  year: 2003
  end-page: 8
  ident: CR21
  article-title: Fatty acid synthase expression in melanoma
  publication-title: J Cutan Pathol.
  doi: 10.1034/j.1600-0560.2003.300104.x
– volume: 5
  start-page: 978
  year: 2006
  end-page: 85
  ident: CR43
  article-title: Growth arrest induced by C75, A fatty acid synthase inhibitor, Was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.5.8.2883
– volume: 24
  start-page: 4169
  year: 2004
  end-page: 73
  ident: CR16
  article-title: Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma
  publication-title: Anticancer Res.
– volume: 84
  start-page: 183
  year: 2004
  end-page: 95
  ident: CR69
  article-title: Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere)
  publication-title: Breast Cancer Res Treat.
  doi: 10.1023/B:BREA.0000018409.59448.60
– volume: 32
  start-page: 30
  year: 2020
  end-page: 40
  ident: CR61
  article-title: Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line
  publication-title: J Chemother
  doi: 10.1080/1120009X.2019.1694761
– volume: 12
  start-page: 1283
  year: 2020
  ident: CR72
  article-title: Fatty acid synthase inhibitor G28 shows anticancer activity in EGFR tyrosine kinase inhibitor resistant lung adenocarcinoma models
  publication-title: Cancers
  doi: 10.3390/cancers12051283
– volume: 78
  start-page: 5397
  year: 2021
  end-page: 413
  ident: CR34
  article-title: Dual regulation of fatty acid synthase (FASN) expression by O-GlcNAc transferase (OGT) and mTOR pathway in proliferating liver cancer cells
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-021-03857-z
– volume: 64
  start-page: 997
  year: 2005
  end-page: 1001
  ident: CR48
  article-title: Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2004.09.027
– volume: 9
  start-page: e97697
  year: 2014
  ident: CR38
  article-title: The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells
  publication-title: PloS ONE
  doi: 10.1371/journal.pone.0097697
– volume: 11
  start-page: e0147717
  year: 2016
  ident: CR40
  article-title: Inhibition of fatty acid synthase decreases expression of stemness markers in glioma stem cells
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0147717
– volume: 1
  start-page: 3339
  year: 2019
  end-page: 47
  ident: CR35
  article-title: Fatty acid synthase enhances colorectal cancer cell proliferation and metastasis via regulating AMPK/mTOR pathway
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S199369
– volume: 59
  start-page: 9683
  year: 2011
  end-page: 90
  ident: CR46
  article-title: Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells
  publication-title: J Agric Food Chem
  doi: 10.1021/jf2021489
– volume: 277
  start-page: L381
  year: 1999
  end-page: 90
  ident: CR8
  article-title: Hormonal regulation and cellular localization of fatty acid synthase in human fetal lung
  publication-title: Am J Physiol
  doi: 10.1152/ajplung.1999.277.2.L381
– volume: 42
  start-page: 289
  year: 2003
  end-page: 317
  ident: CR2
  article-title: Structural and functional organization of the animal fatty acid synthase
  publication-title: Prog Lipid Res
  doi: 10.1016/s0163-7827(02)00067-x
– ident: CR11
– volume: 7
  start-page: 2257
  year: 2008
  end-page: 67
  ident: CR49
  article-title: Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase
  publication-title: Cell Cycle
  doi: 10.4161/cc.7.14.6475
– volume: 32
  start-page: 2471
  year: 2014
  end-page: 6
  ident: CR19
  article-title: Expression and roles of fatty acid synthase in hepatocellular carcinoma
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3484
– volume: 100
  start-page: 6358
  year: 2003
  end-page: 63
  ident: CR6
  article-title: Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.0931394100
– volume: 306
  start-page: E1132
  year: 2014
  end-page: 43
  ident: CR7
  article-title: Fatty acid synthase is required for mammary gland development and milk production during lactation
  publication-title: Am J Physiol Endocrinol Metab.
  doi: 10.1152/ajpendo.00514.2013
– volume: 109
  start-page: 11818
  year: 2012
  end-page: 23
  ident: CR23
  article-title: Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1205995109
– volume: 12
  start-page: 100155
  year: 2021
  ident: CR37
  article-title: Fatty acid synthase as a feasible biomarker for triple negative breast cancer stem cell subpopulation cultured on electrospun scaffolds
  publication-title: Mater Today Bio
  doi: 10.1016/j.mtbio.2021.100155
– volume: 49
  start-page: 739
  year: 2010
  end-page: 49
  ident: CR47
  article-title: The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells
  publication-title: Mol Carcinog
  doi: 10.1002/mc.20649
– volume: 20
  start-page: 2027
  year: 2006
  end-page: 35
  ident: CR53
  article-title: Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor
  publication-title: FASEB J
  doi: 10.1096/fj.05-5404com
– volume: 40
  start-page: 71
  year: 2002
  end-page: 9
  ident: CR14
  article-title: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach
  publication-title: Histopathology
  doi: 10.1046/j.1365-2559.2002.01289.x
– volume: 10
  start-page: 171
  year: 2014
  end-page: 80
  ident: CR45
  article-title: Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.7357
– volume: 38
  start-page: 445
  year: 2022
  end-page: 52
  ident: CR4
  article-title: L’acide gras synthase, une enzyme «multi-FASette»
  publication-title: Med Sci
  doi: 10.1051/medsci/2022062
– volume: 142
  start-page: 2447
  year: 2016
  end-page: 59
  ident: CR22
  article-title: Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-016-2249-6
– volume: 45
  start-page: 485
  year: 2014
  end-page: 92
  ident: CR26
  article-title: Lipogenesis in cancer progression
  publication-title: Int J Oncol.
  doi: 10.3892/ijo.2014.2441
– ident: CR66
– volume: 77
  start-page: CT153
  year: 2017
  ident: CR63
  article-title: Abstract CT153: first in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2017-CT153
– volume: 140
  start-page: 1071
  year: 2011
  end-page: 83
  ident: CR31
  article-title: Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.12.006
– volume: 50
  start-page: 206
  year: 2018
  end-page: 18
  ident: CR52
  article-title: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
  publication-title: Nat Genet
  doi: 10.1038/s41588-017-0027-2
– volume: 23
  start-page: 1
  year: 2022
  end-page: 8
  ident: CR41
  article-title: Lipid metabolism of cancer stem cells
  publication-title: Oncol Lett.
  doi: 10.3892/ol.2022.13239
– volume: 66
  start-page: 1192
  year: 2011
  end-page: 200
  ident: CR9
  article-title: Aging is associated with a shift of fatty metabolism toward lipogenesis
  publication-title: J Gerontol A Biol Sci Med Sci
  doi: 10.1093/gerona/glr124
– volume: 16
  start-page: 499
  year: 2017
  end-page: 507
  ident: CR24
  article-title: Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2017.1282586
– volume: 9
  start-page: e003093
  year: 2021
  ident: CR57
  article-title: PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-003093
– volume: 22
  start-page: 5337
  year: 2016
  end-page: 48
  ident: CR28
  article-title: Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2973
– volume: 591
  start-page: 306
  year: 2021
  end-page: 11
  ident: CR58
  article-title: Lipid signalling enforces functional specialization of Treg cells in tumours
  publication-title: Nature
  doi: 10.1038/s41586-021-03235-6
– volume: 91
  start-page: 6379
  year: 1994
  end-page: 83
  ident: CR10
  article-title: Fatty acid synthesis: a potential selective target for antineoplastic therapy
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.91.14.6379
– volume: 18
  start-page: 2380
  year: 2009
  end-page: 5
  ident: CR17
  article-title: Serum fatty acid synthase as a marker of pancreatic neoplasia
  publication-title: Cancer Epidemiol Biomark Prev.
  doi: 10.1158/1055-9965.EPI-09-0144
– volume: 1864
  start-page: 344
  year: 2019
  end-page: 57
  ident: CR27
  article-title: A specific lipid metabolic profile is associated with the epithelial mesenchymal transition program
  publication-title: Biochim Biophys Acta Mol Cell Biol Lipids
  doi: 10.1016/j.bbalip.2018.12.011
– volume: 13
  start-page: 1132
  year: 2021
  ident: CR67
  article-title: Fatty acid synthase confers tamoxifen resistance to ER+/HER2+ breast cancer
  publication-title: Cancers
  doi: 10.3390/cancers13051132
– volume: 115
  start-page: 19
  year: 2005
  end-page: 35
  ident: CR70
  article-title: Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity
  publication-title: Int J Cancer
  doi: 10.1002/ijc.20754
– volume: 101
  start-page: 519
  year: 2009
  end-page: 32
  ident: CR13
  article-title: Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djp030
– volume: 10
  start-page: 549
  year: 2010
  end-page: 54
  ident: CR15
  article-title: High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.10.6.12727
– volume: 32
  year: 2015
  ident: CR18
  article-title: Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0391-z
– volume: 23
  start-page: 105
  year: 2022
  ident: CR20
  article-title: Evaluation of the expression of fatty acid synthase and O-GlcNAc transferase in patients with liver cancer by exploration of transcriptome databases and experimental approaches
  publication-title: Oncol Lett
  doi: 10.3892/ol.2022.13225
– volume: 5
  year: 2015
  ident: CR50
  article-title: Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma
  publication-title: Sci Rep
  doi: 10.1038/srep14752
– volume: 2
  start-page: 414
  year: 2021
  end-page: 28
  ident: CR51
  article-title: Fatty acid synthesis is required for breast cancer brain metastasis
  publication-title: Nat Cancer
  doi: 10.1038/s43018-021-00183-y
– volume: 12
  start-page: 411
  year: 2004
  end-page: 22
  ident: CR71
  article-title: Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells
  publication-title: Oncol Rep
– volume: 10
  start-page: e8313
  year: 2018
  ident: CR39
  article-title: Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.201708313
– volume: 9
  start-page: 2927
  year: 2018
  ident: CR60
  article-title: Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.02927
– volume: 187
  start-page: 375
  year: 2021
  end-page: 86
  ident: CR64
  article-title: FASN inhibition as a potential treatment for endocrine-resistant breast cancer
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-021-06231-6
– volume: 20
  start-page: 247
  year: 2021
  end-page: 50
  ident: CR65
  article-title: Targeted protein degraders crowd into the clinic
  publication-title: Nat Rev Drug Disco
  doi: 10.1038/d41573-021-00052-4
– volume: 150
  start-page: 201
  year: 1997
  end-page: 8
  ident: CR12
  article-title: Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia
  publication-title: Am J Pathol.
– volume: 11
  start-page: 725137
  year: 2021
  ident: CR33
  article-title: Oncogenic integration of nucleotide metabolism via fatty acid synthase in non-hodgkin lymphoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.725137
– volume: 18
  start-page: 973
  year: 2007
  end-page: 80
  ident: CR68
  article-title: Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells
  publication-title: Oncol Rep
– volume: 35
  start-page: 1341
  year: 2014
  end-page: 51
  ident: CR56
  article-title: Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgu042
– volume: 28
  start-page: 866
  year: 2018
  end-page: 80.e15
  ident: CR54
  article-title: Impairment of angiogenesis by fatty acid synthase inhibition involves mTOR malonylation
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.07.019
– volume: 1
  start-page: 1667
  year: 2004
  end-page: 76
  ident: CR3
  article-title: Head-to-head coiled arrangement of the subunits of the animal fatty acid synthase
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2004.09.016
– volume: 85
  start-page: 321
  year: 2020
  end-page: 30
  ident: CR59
  article-title: The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma
  publication-title: Cancer Chemother Pharm
  doi: 10.1007/s00280-019-04010-1
– volume: 132
  start-page: e148550
  year: 2022
  ident: CR62
  article-title: Clinical development of metabolic inhibitors for oncology
  publication-title: J Clin Invest
  doi: 10.1172/JCI148550
– volume: 35
  start-page: 2651
  year: 2016
  end-page: 6
  ident: CR44
  article-title: Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4682
– volume: 24
  start-page: 4169
  year: 2004
  ident: 460_CR16
  publication-title: Anticancer Res.
– volume: 306
  start-page: E1132
  year: 2014
  ident: 460_CR7
  publication-title: Am J Physiol Endocrinol Metab.
  doi: 10.1152/ajpendo.00514.2013
– volume: 32
  start-page: 807
  year: 2017
  ident: 460_CR32
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.11.011
– volume: 45
  start-page: 485
  year: 2014
  ident: 460_CR26
  publication-title: Int J Oncol.
  doi: 10.3892/ijo.2014.2441
– volume: 1864
  start-page: 344
  year: 2019
  ident: 460_CR27
  publication-title: Biochim Biophys Acta Mol Cell Biol Lipids
  doi: 10.1016/j.bbalip.2018.12.011
– volume: 591
  start-page: 306
  year: 2021
  ident: 460_CR58
  publication-title: Nature
  doi: 10.1038/s41586-021-03235-6
– volume: 38
  start-page: 445
  year: 2022
  ident: 460_CR4
  publication-title: Med Sci
  doi: 10.1051/medsci/2022062
– volume: 16
  start-page: 499
  year: 2017
  ident: 460_CR24
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2017.1282586
– volume: 109
  start-page: 11818
  year: 2012
  ident: 460_CR23
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1205995109
– volume: 22
  start-page: 5337
  year: 2016
  ident: 460_CR28
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2973
– volume: 97
  start-page: 686
  year: 1992
  ident: 460_CR1
  publication-title: Am J Clin Pathol
  doi: 10.1093/ajcp/97.5.686
– volume: 35
  start-page: 2651
  year: 2016
  ident: 460_CR44
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4682
– volume: 28
  start-page: 866
  year: 2018
  ident: 460_CR54
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.07.019
– volume: 91
  start-page: 6379
  year: 1994
  ident: 460_CR10
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.91.14.6379
– volume: 13
  start-page: 1132
  year: 2021
  ident: 460_CR67
  publication-title: Cancers
  doi: 10.3390/cancers13051132
– volume: 18
  start-page: 2380
  year: 2009
  ident: 460_CR17
  publication-title: Cancer Epidemiol Biomark Prev.
  doi: 10.1158/1055-9965.EPI-09-0144
– volume: 2
  start-page: 414
  year: 2021
  ident: 460_CR51
  publication-title: Nat Cancer
  doi: 10.1038/s43018-021-00183-y
– volume: 49
  start-page: 739
  year: 2010
  ident: 460_CR47
  publication-title: Mol Carcinog
  doi: 10.1002/mc.20649
– volume: 20
  start-page: 2027
  year: 2006
  ident: 460_CR53
  publication-title: FASEB J
  doi: 10.1096/fj.05-5404com
– volume: 32
  start-page: 30
  year: 2020
  ident: 460_CR61
  publication-title: J Chemother
  doi: 10.1080/1120009X.2019.1694761
– volume: 23
  start-page: 1
  year: 2022
  ident: 460_CR41
  publication-title: Oncol Lett.
  doi: 10.3892/ol.2022.13239
– volume: 187
  start-page: 375
  year: 2021
  ident: 460_CR64
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-021-06231-6
– volume: 9
  start-page: e003093
  year: 2021
  ident: 460_CR57
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-003093
– volume: 78
  start-page: 5397
  year: 2021
  ident: 460_CR34
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-021-03857-z
– volume: 18
  start-page: 973
  year: 2007
  ident: 460_CR68
  publication-title: Oncol Rep
– volume: 277
  start-page: L381
  year: 1999
  ident: 460_CR8
  publication-title: Am J Physiol
  doi: 10.1152/ajplung.1999.277.2.L381
– volume: 30
  start-page: 23
  year: 2003
  ident: 460_CR21
  publication-title: J Cutan Pathol.
  doi: 10.1034/j.1600-0560.2003.300104.x
– volume: 107
  start-page: 977
  year: 2012
  ident: 460_CR55
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.355
– volume: 100
  start-page: 6358
  year: 2003
  ident: 460_CR6
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.0931394100
– volume: 115
  start-page: 19
  year: 2005
  ident: 460_CR70
  publication-title: Int J Cancer
  doi: 10.1002/ijc.20754
– volume: 11
  start-page: 725137
  year: 2021
  ident: 460_CR33
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.725137
– volume: 12
  start-page: 100155
  year: 2021
  ident: 460_CR37
  publication-title: Mater Today Bio
  doi: 10.1016/j.mtbio.2021.100155
– volume: 101
  start-page: 519
  year: 2009
  ident: 460_CR13
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djp030
– volume: 142
  start-page: 2447
  year: 2016
  ident: 460_CR22
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-016-2249-6
– volume: 32
  year: 2015
  ident: 460_CR18
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0391-z
– volume: 321
  start-page: 1315
  year: 2008
  ident: 460_CR5
  publication-title: Science
  doi: 10.1126/science.1161269
– ident: 460_CR11
  doi: 10.1111/j.1365-2184.2007.00498.x
– volume: 5
  year: 2015
  ident: 460_CR50
  publication-title: Sci Rep
  doi: 10.1038/srep14752
– volume: 35
  start-page: 1341
  year: 2014
  ident: 460_CR56
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgu042
– volume: 40
  start-page: 71
  year: 2002
  ident: 460_CR14
  publication-title: Histopathology
  doi: 10.1046/j.1365-2559.2002.01289.x
– volume: 5
  start-page: 978
  year: 2006
  ident: 460_CR43
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.5.8.2883
– volume: 10
  start-page: 171
  year: 2014
  ident: 460_CR45
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.7357
– volume: 11
  start-page: e0147717
  year: 2016
  ident: 460_CR40
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0147717
– volume: 150
  start-page: 201
  year: 1997
  ident: 460_CR12
  publication-title: Am J Pathol.
– volume: 7
  start-page: 2257
  year: 2008
  ident: 460_CR49
  publication-title: Cell Cycle
  doi: 10.4161/cc.7.14.6475
– volume: 12
  start-page: 411
  year: 2004
  ident: 460_CR71
  publication-title: Oncol Rep
– volume: 77
  start-page: CT153
  year: 2017
  ident: 460_CR63
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2017-CT153
– volume: 144
  start-page: 646
  year: 2011
  ident: 460_CR25
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 10
  start-page: 549
  year: 2010
  ident: 460_CR15
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.10.6.12727
– volume: 64
  start-page: 997
  year: 2005
  ident: 460_CR48
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2004.09.027
– volume: 37
  start-page: 110174
  year: 2021
  ident: 460_CR29
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.110174
– volume: 9
  start-page: 2927
  year: 2018
  ident: 460_CR60
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.02927
– volume: 1
  start-page: 3339
  year: 2019
  ident: 460_CR35
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S199369
– volume: 32
  start-page: 2471
  year: 2014
  ident: 460_CR19
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3484
– volume: 66
  start-page: 1192
  year: 2011
  ident: 460_CR9
  publication-title: J Gerontol A Biol Sci Med Sci
  doi: 10.1093/gerona/glr124
– volume: 140
  start-page: 1071
  year: 2011
  ident: 460_CR31
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.12.006
– volume: 9
  start-page: e97697
  year: 2014
  ident: 460_CR38
  publication-title: PloS ONE
  doi: 10.1371/journal.pone.0097697
– volume: 84
  start-page: 183
  year: 2004
  ident: 460_CR69
  publication-title: Breast Cancer Res Treat.
  doi: 10.1023/B:BREA.0000018409.59448.60
– volume: 59
  start-page: 9683
  year: 2011
  ident: 460_CR46
  publication-title: J Agric Food Chem
  doi: 10.1021/jf2021489
– volume: 23
  start-page: 105
  year: 2022
  ident: 460_CR20
  publication-title: Oncol Lett
  doi: 10.3892/ol.2022.13225
– volume: 63
  start-page: 3799
  year: 2003
  ident: 460_CR42
  publication-title: Cancer Res
– volume: 50
  start-page: 206
  year: 2018
  ident: 460_CR52
  publication-title: Nat Genet
  doi: 10.1038/s41588-017-0027-2
– volume: 12
  start-page: 1283
  year: 2020
  ident: 460_CR72
  publication-title: Cancers
  doi: 10.3390/cancers12051283
– volume: 85
  start-page: 321
  year: 2020
  ident: 460_CR59
  publication-title: Cancer Chemother Pharm
  doi: 10.1007/s00280-019-04010-1
– volume: 12
  year: 2010
  ident: 460_CR36
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2777
– volume: 20
  start-page: 247
  year: 2021
  ident: 460_CR65
  publication-title: Nat Rev Drug Disco
  doi: 10.1038/d41573-021-00052-4
– volume: 42
  start-page: 289
  year: 2003
  ident: 460_CR2
  publication-title: Prog Lipid Res
  doi: 10.1016/s0163-7827(02)00067-x
– ident: 460_CR66
  doi: 10.3892/ijo.31.4.769
– volume: 75
  start-page: 2530
  year: 2015
  ident: 460_CR30
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-0202
– volume: 1
  start-page: 1667
  year: 2004
  ident: 460_CR3
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2004.09.016
– volume: 132
  start-page: e148550
  year: 2022
  ident: 460_CR62
  publication-title: J Clin Invest
  doi: 10.1172/JCI148550
– volume: 10
  start-page: e8313
  year: 2018
  ident: 460_CR39
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.201708313
SSID ssj0000561655
Score 2.5227835
SecondaryResourceType review_article
Snippet An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme fatty...
Abstract An accelerated de novo lipogenesis (DNL) flux is a common characteristic of cancer cells required to sustain a high proliferation rate. The DNL enzyme...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 16
SubjectTerms 631/154/53
631/67/395
Angiogenesis
Apoptosis
Cancer
Cancer therapies
Cell activation
Cell Biology
Cell death
Cell growth
Cell proliferation
Chemotherapy
Enzymes
ErbB-2 protein
Fatty acids
Fatty-acid synthase
Human Genetics
Immunoregulation
Inflammation
Internal Medicine
Lipid rafts
Lipogenesis
Localization
Lymphocytes T
Macrophages
Medicine
Medicine & Public Health
Metastases
Oncology
Protein biosynthesis
Review
Review Article
Tumor microenvironment
SummonAdditionalLinks – databaseName: Science Database (ProQuest)
  dbid: M2P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9UwELagINQL-xIoyEjcwKoTO4nNBQGiAolWPQDqLbIdu42gTpukSI8rf5yx4_eqx9IL13jibT6Px57xDELPlKkE41oSOHtUhDvHiQQ1nqjclpJpWZtoPf_ysd7bEwcHcj9duI3JrXIpE6OgbnsT7si3C0CWlOHC4tXJKQlZo4J1NaXQuIyugGaTB5eu3WJ_dccStOOqLNNbGcrE9siDYY7ARkXis0ki1vajGLb_b7rmny6Tv9lN43a0c-N_B3ITXU-KKH49I-cWumT9bXRtN5na76CfHzxIrhhNfMK9w6AoYmiJ9N70ALrOYOt_LI4tdmqaFliZrsXjwk9HsC3izkf6kKjlWA1fx1CBCfgaXmIVqgF0wbDw7IceyIHBHZlJ8PwmDI7wd9HnnXef3r4nKWMDMSXPJ6KdsNxVyhSy0kK7QquWO9G2uuZcGUu1kKo2oJQ5Sa0pLDUFNXAWttaUklfsHtrwvbcPEKauVUqAMmMLBsK81kxamUtdGDgh5s5mKF_yrTEpnHnIqvGtiWZ1JpqZ1w3wuom8bkSGnq_-OZmDeVxI_SbAYUUZAnHHD_1w2KR13cAC0FqaECmu5pWjCkRgXmquqHUyVzRDW0sUNEk6jM05BDL0dFUMMx-MNcrb_izSAFFwIszQ_Rl7q56wSjJORZ0hsYbKta6ul_juKMYODxF3eU2h4RdLAJ_3699z8fDiYTxCm0VcU4zkYgttTMOZfYyumu9TNw5P4qL8BQg-QGo
  priority: 102
  providerName: ProQuest
Title Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies
URI https://link.springer.com/article/10.1038/s41389-023-00460-8
https://www.ncbi.nlm.nih.gov/pubmed/36934087
https://www.proquest.com/docview/2787994222
https://www.proquest.com/docview/2788798554
https://pubmed.ncbi.nlm.nih.gov/PMC10024702
https://doaj.org/article/ccabb9c0240746f0a25715b4a0ef91a0
Volume 12
WOSCitedRecordID wos000952323000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2157-9024
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000561655
  issn: 2157-9024
  databaseCode: DOA
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2157-9024
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000561655
  issn: 2157-9024
  databaseCode: M~E
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nj9QgFCe6GuPF-G11nWDiTcnSQgt4c81s3MSZNEbNeGqAgWyj25pp12Q8ePEf90E7446fFy8cymt5efyA9_rgB0KPtS0k40YRiD0Kwr3nRIEbT3TqcsWMEjZmz9-9EvO5XCxUee6qr7AnbKAHHgx3AC0Yo2yg4hK88FQDxtLccE2dV6mO0ToV6lwwNbB6F2mR5-MpGcrkQcdDSo7AEkXigUkid1aiSNj_Oy_z182SP2VM40J0dB1dGz1I_HzQ_Aa64Jqb6MpszJHfQt-OG5hyIg14j1uPwcPD0B5pG9sCWmqLXfNlfeqw132_xtrWS9ytm_4E1jNcN1E-3LByqlcfuvABG4CxeoZ1-AzAArTCwwbyIA49U5NBBA-HuSD2vo3eHk3fvHhJxqsWiM152hPjpeO-0DZThZHGZ0YvuZfLpRGca-uokUoLC96UV9TZzFGbUQtBrHM2V7xgd9Be0zbuHsLUL7WW4IW4jMEsLAxTTqXKZBZCu9S7BKUbs1d25CEP12F8rGI-nMlq6KoKuqqKXVXJBD3ZvvNpYOH4q_Rh6M2tZGDQjg8AV9WIq-pfuErQ_gYL1TisuyqD6U2p8NcsQY-21WD5kGXRjWvPogwIhd1_Cbo7QGerCSsU41SKBMkdUO2oulvT1CeR9DtQ5XJBoeGnG_z90OvPtrj_P2zxAF3N4sBhJJX7aK9fnbmH6LL93NfdaoIuioWIpZygS4fTefl6EkcjlLOsDKWI5dcp1JfHs_L9dywbOrI
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9UwELZKQcCFfQkUMBKcwGoWJ7GREGKr-tTXpx4K6s3Yjk0jaFKSFPS48n_4jYyd5FWPpbceuCYTx5l8s9gznkHokdQZS6jiBNYeGaHWUsLBjScyMilPFM-1j56_n-azGdvb4zsr6Od4FsalVY460SvqotZuj3w9BmRx7jYsXhx-Ia5rlIuuji00elhsmfk3WLK1zydv4P8-juONt7uvN8nQVYDolEYdUZYZajOpY54ppmysZEEtKwqVUyq1CRXjMtfgOFgeGh2bUMehhvWaMTrlNEtg3DPoLHWVxVyqYLyz2NNx3niWpsPZnDBh6y11gUAChpH4Y5qELdk_3ybgb77tnymav8VpvfnbuPy_Me4KujQ42vhlLxlX0YqprqHz20MqwXX0Y1KBZvbV0jtcWwyOMIYvI3WlaxCqUmNTfZ8fGGxl182x1GWB23nV7YPZx2Xl6V0jmgPZfGrdANrJT_MMSzcMSA-wEfd59o4cAFySngT3Z95K095A706FBTfRalVX5jbCoS2kZOCsmTgBY5WrhBsecRVrWAFH1gQoGnEi9FCu3XUN-Sx82kDCRI8tAdgSHluCBejJ4pnDvljJidSvHPwWlK7QuL9QNx_FoLcECLhSXLtKeDnNbChBxUepojI0lkcyDNDaiDoxaL9WHEMuQA8Xt4HzLhglK1MfeRogckmSAbrVY30xkyTjCQ1ZHiC2JAVLU12-U5X7vja6qyhM8xBe_HQUmON5_ZsXd07-jAfowubu9lRMJ7Otu-hi7OU5IRFbQ6tdc2TuoXP6a1e2zX2vEDD6cNqC9AuroKEP
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELbKFlVceD8CBYwEJ7A2DyexkRACyopV29UeALWnYDs2jaBJ2aSg5cq_4tcxdh7V8uitB66bWa8z-33jsWc8g9BDoRIWUckJ7D0SQo2hhIMbT0SgYx5JnioXPX-_k85mbG-Pz9fQz_4ujE2r7G2iM9R5pewZ-TgEZHFuDyzGpkuLmG9Nnh99IbaDlI209u00Wohs6-U32L7Vz6Zb8F8_CsPJ67ev3pCuwwBRMQ0aIg3T1CRChTyRTJpQipwalucypVQo7UvGRarAiTDc1yrUvgp9BXs3rVXMaRLBuOfQOrjkNByh9fl0d74_nPBY3zyJ4-6mjh-xcU1tWJDAMkncpU3CVlZD1zTgb57unwmbv0Vt3WI4ufQ_q_Eyuti54PhFy5kraE2XV9HGbpdkcA39mJZgs10d9QZXBoOLjOEtSVWqCuhWKKzL78tDjY1omiUWqshxvSybA3AIcFE6edui5lAsPtV2AGWZtXiKhR0GeAUqxW0GvhUHaBekFcHtbbhC19fRuzNRwQ00KqtS30LYN7kQDNw4HUawjKUy4poHXIYK9saB0R4KesxkqivkbvuJfM5cQkHEshZnGeAsczjLmIceD985asuYnCr90kJxkLQlyN0H1eJj1lm0DKgvJVe2Rl5KE-MLMP5BLKnwteGB8D202SMw6-xinZ3Az0MPhsegeRumEqWujp0MCNn0SQ_dbHE_zCRKeER9lnqIrTBiZaqrT8riwFVNt7WGaerDDz_pyXMyr3_r4vbpr3EfbQB_sp3pbPsOuhA6akckYJto1CyO9V10Xn1tinpxr7MOGH04ayb9AsVxq1g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+the+pro-oncogenic+enzyme+fatty+acid+synthase+in+the+hallmarks+of+cancer%3A+a+promising+target+in+anti-cancer+therapies&rft.jtitle=Oncogenesis+%28New+York%2C+NY%29&rft.au=Vanauberg%2C+Dimitri&rft.au=Schulz%2C+C%C3%A9line&rft.au=Lefebvre%2C+Tony&rft.date=2023-03-18&rft.issn=2157-9024&rft.eissn=2157-9024&rft.volume=12&rft.issue=1&rft.spage=16&rft_id=info:doi/10.1038%2Fs41389-023-00460-8&rft_id=info%3Apmid%2F36934087&rft.externalDocID=36934087
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2157-9024&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2157-9024&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2157-9024&client=summon